The rigid 4.5-hour window for stroke thrombolysis may be unnecessarily restrictive for patients whose brain imaging reveals salvageable tissue. This represents a potential paradigm shift that could expand treatment access for thousands of stroke patients who currently fall outside therapeutic windows.
This clinical trial evaluated intravenous tenecteplase administration in acute ischemic stroke patients presenting 4.5 to 24 hours after symptom onset, specifically targeting cases involving non-large vessel occlusions where brain imaging demonstrated salvageable tissue. The research focused on patients who traditionally would be considered beyond the therapeutic window for clot-dissolving medications, using advanced imaging criteria to identify candidates with viable brain tissue despite delayed presentation.
The findings challenge decades of stroke care dogma that has strictly limited thrombolytic therapy to the first few hours after symptom onset. Current guidelines emerged from early trials that used time-based rather than tissue-based selection criteria, potentially excluding patients who could benefit from treatment. This tissue-centric approach represents a more personalized medicine model, where treatment decisions rely on biological markers of brain viability rather than arbitrary time cutoffs. However, the study focused specifically on non-large vessel occlusions, which represent a subset of stroke cases and may not extend to all stroke subtypes. The research also required sophisticated imaging capabilities that may not be universally available, raising questions about real-world implementation. While promising, this represents early evidence that requires validation across diverse populations and healthcare systems before fundamentally changing stroke treatment protocols.